This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $371,150 to Virginia Polytechnic Institute & State University (Virginia Tech) to characterize a novel Brucella small RNA called BSR7 that is critical for cell envelope integrity.
The research aims to determine if deletion of BSR7 leads to attenuation of the Brucella abortus bacteria in macrophage and animal infection models. Additionally, the project will investigate if BSR7 is produced under biologically relevant conditions and regulates genes important for the infectivity of B. abortus. This work may inform the development of new therapeutic and vaccine strategies against human Brucella infections, which can cause debilitating disease and are considered potential biological threats. The award period runs from June 2024 through April 2026.
Generated 4/1/25, 5:12 AM